meta|Evidence - COVID-19
click on circles to display study description...
vitamin C (n=27) vs. placebo (n=29)
randomized controlled trial some concerns about risk of bias
High-dose intravenous Vitamin C
24 g vitamin C per day. Patients were infused with 12 g vitamin C diluted in 50 ml of bacteriostatic water every 12 h at a rate of 12 ml/hour by infusion pump for 7 days.
Placebo
50 ml of bacteriostatic water infused every 12 h at a rate of 12 ml/hour by infusion pump for 7 days.
Patients were randomized to receive vitamin C or placebowithin 48 h after admission to the ICU.
COVID-19 severe or critically
(1) age ≥ 18 and < 80 years; (2) RTPCR positive for SARS-CoV-2; (3) pneumonia confirmed by chest imaging and admission to the ICU; (3) PaO2/ FiO2(P/F) < 300 mmHg.
Double-blind.
Multicenter, 3 hospitals in Hubei, China.
vitamin C (n=30) vs. standard of care (n=30)
randomized controlled trial high risk of bias
Vitamin C (high dose)
Vitamin C at a dose of 6g daily (1.5 grams vitamin C IV every six hours for five days) plus standard treatment.
Standard treatment
All of the participants were also treated with oral Lopinavir/Ritonavir (Kaletra, Abbott Laboratories) 400/100 mg twice daily and daily dose of oral Hydroxychloroquine (400 mg) according to the Iranian COVID-19 treatment protocol at time of this study.Some of the patients deteriorated during the admission and received corticosteroid (methylprednisolone 125 mg daily for three days) and IVIG (5 to 10 gr daily for three to ve days).
COVID-19 severe or critically
Age older than 18 years, positive COVID-19 polymerase chain reaction (PCR) test or COVID-19 suspicion based on clinical findings (mainly fever, dyspnea, dry cough), imaging findings of COVID-19 on spiral chest computer tomography (CT) or high resolution CT (HRCT) imagings validated by a trained radiologist, clinical manifestations of ARDS or myocarditis, and oxygen saturation lower than 93% from admission or after 48 hours from the first COVID-19 treatment.
Open-label.
Single center, Ziaeian Hospital, Tehran, Iran.
vitamin C (n=75) vs. standard of care (n=75)
- risk of bias NA
Vitamin C
50 mg/kg/day of intravenous Vitamin C in addition to standard therapy for COVID-19 infection.
Standard of care
Antipyretics, dexamethasone, and prophylactic antibiotics.
Standard therapy in both groups.
COVID-19 severe or critically
Patients who needed mechanical ventilation within 12 hours of admission were excluded from the study.
Open-label.
Single-center, tertiary care hospital in Karachi, Pakistan.
Several outcomes were compared for both groups: number of days required for the disappearance of symptoms, number of days spent in the hospital, need for ventilation, and mortality.
Vitamin D (n=274) vs. control (n=269)
randomized controlled trial high risk of bias
oral bolus of cholecalciferol (100,000 IU) administered at hospital admission
No vitamin D
COVID-19 severe or critically
open-label
multicentre, international
powered by vis.js Network